Left Main Intervention: Will it become standard of care?
|
|
- Katrina McGee
- 6 years ago
- Views:
Transcription
1 Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Laa Fall Fellows Course Las Vegas 2014
2 Disclosures Advisory Board: Abbott Vascular Boston Scientific Medtronic, Inc. themedicinescompany
3
4 Medicine Changes!!! Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults There is no evidence to support continued use of specific LDL treatment targets. Will IMPROVE-IT change GDL s again?
5 PCI vs CABG
6 PCI for LM PCI of LM attractive: Large diameter vessel Proximal location BUT.. Lots of LM disease involves the bifurcation (high risk of restenosis) Many patients have multivessel CAD: potential survival benefit with CABG FREEDOM and SYNTAX TRIALS
7 SYNTAX SCORE: Risk Stratify
8 MACCE to 5 Years Left Main Subset N=705 TAXUS (N=357) CABG (N=348) 1-2 years* 13.7% vs 15.8% 7.5% vs 10.3% P=0.44 P=0.22 Cumulative Event Rate (%) Before 1 year* years* 5.2% vs 5.7% P= years* 6.4% vs 8.3% P= % P= years* 5.9% vs 5.5% P= % Months Since Allocation Cumulative KM Event Rate ± 1.5 SE Serruys PW et al. Lancet 2013;381: log-rank P value;*binary rates SYNTAX 3VD 5-year Outcomes TCT 2012 Serruys 23 October 2012 Slide
9 Left Main Disease 5-year Outcomes (N=705) CABG (n=348) P=0.53 P=0.10 TAXUS (n=357) P=0.03 P<0.001 P= Patients (%) 31.0 All Death MI CVA Revasc. Mohr FW et al. Lancet 2013;381: SYNTAX 3VD 5-year Outcomes TCT 2012 Mohr 23 October 2012 Slide 9 MACCE
10 MACCE to 5 Years by SYNTAX Score Tercile LM Subset High Scores 33 CABG (N=149) TAXUS (N=135) LM Disease MACCE (%) % P= % Months CABG PCI P value Death 14.1% 20.9% 0.11 CVA 4.9% 1.6% 0.13 MI 6.1% 11.7% 0.13 Death, CVA or MI 22.1% 26.1% 0.40 Revasc. 11.6% 34.1% <0.001 Serruys PW et al. Lancet 2013;381: SYNTAX 3VD 5-year Outcomes TCT 2012 Serruys 23 October 2012 Slide 10
11 MACCE to 5 Years by SYNTAX Score Tercile Low to Intermediate Scores (0-32) CABG (N=196) TAXUS (N=221) LM Disease Cumulative Event Rate (%) 50 PCI P value Death 15.1% 7.9% 0.02 CVA 3.9% 1.4% 0.11 MI 3.8% 6.1% 0.33 Death, CVA or MI 19.8% 14.8% 0.16 Revasc. 18.6% 22.6% 0.36 P= % 31.3% 25 0 CABG Months Since Allocation Serruys PW et al. Lancet 2013;381: SYNTAX 3VD 5-year Outcomes TCT 2012 Serruys 23 October 2012 Slide 11
12 Bottom Line Benefit with CABG over PCI is limited to fewer repeat revascularizations, at a cost of more strokes High SYNTAX score patients (>33) benefit from CABG
13 I d rather die than have a stroke What kind of stroke will I have? A mini-stroke or a Big One???
14 Most patients prefer repci to the risk of CVA
15 ACC/AHA Guidelines for Revascularization of Left Main Disease: Pre-2009 I IIa IIb III CABG PCI Kushner et. Al. JACC Vol 54. No 23, 2009 Post-2009 I IIa IIb III CABG PCI
16 ACC/AHA Guidelines IIa LMCA PCI is reasonable in pts with class III angina and >50% LM stenosis who are not eligible for CABG IIb Stenting of the LMCA as an alternative to CABG may be considered in pts with anatomic conditions that are associated with a low risk of PCI procedural complications and clinical conditions that predict an increased risk of adverse surgical outcomes ACC/AHA 2009 Focused Updates for STEMI and PCI. Circulation 2009;120:
17 ACC/AHA/SCAI GDLS 2009 focused update of PCI GDL Class IIb, LoE B recommendation the best case for PCI as an alternative to CABG for LM CAD is in ostial and midbody lesions without additional multivessel disease Routine angiographic follow-up after LM PCI omitted from guidelines
18 PCI vs CABG for Left Main v Is PCI really non-inferior or superior to CABG in Syntax Score <33 pts with LM ds. for the events that really matter (death, stroke, or MI)? v Can PCI outcomes be improved by..? Use of better DES? (e.g. XIENCE V) Use of better pharmacotherapy (e.g. bivalirudin) IVUS/FFR? (used in <10% in SYNTAX) More frequent staging? (14% in SYNTAX) Avoidance of routine angiographic FU*? v Can CABG outcomes be further improved? *Currently not recommended by the ACC/AHA Guidelines. Circulation 2009;120:
19 EXCEL: Study Design 3600 pts with unprotected left main 165 international sites SYNTAX score 32 Consensus agreement by heart team Yes (N=2600) Enrollment registry R PCI (Xience Prime) (N=1300) No (N=1000) CABG (N=1300) Clinical follow-up: 1 mo, 6 mo and yearly through 5 years
20 What is Novel About EXCEL? The primary endpoint: Death, MI or stroke at 3 years
21 MACCE to 3 Years by SYNTAX Score Tercile LM Subset Low to Intermediate Scores (0-32) CABG (N=196) TAXUS (N=221) Left Main Disease Cumulative Event Rate (%) 40 P= % 20.5% Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value Two-year Outcomes of the SYNTAX Trial CABG PCI P value Death 9.0% 3.7% 0.02 CVA 3.3% 0.9% 0.09 MI 2.6% 4.6% 0.33 Death, CVA or MI 13.2% 8.7% 0.12 Revasc. 13.7% 15.7% 0.61 EOC unblinding
22 What is Novel About EXCEL? Restriction of enrollment to Syntax Score 32
23 What is Novel About EXCEL? Use of 2 nd Generation DES
24 What is Novel About EXCEL? Optimal PCI and CABG Technique
25 EXCEL Evaluation of Xience Prime versus CABG for Effectiveness of Left Main Revascularization Inclusion Criteria Clinical and anatomic eligibility for both PCI and CABG by heart team consensus Silent ischemia, stable angina, unstable angina or recent MI Significant LM disease by heart team consensus - Angiographic DS 70%, or - Angiographic DS 50% to <70% with - a markedly positive noninvasive study, and/or - IVUS MLA <6.0 mm2, and/or - FFR <0.80
26 EXCEL: PCI Procedure Highlights DAPT and statin pre-loading: Required IVUS: Strongly recommended to guide LM PCI FFR: Strongly recommended to assess borderline lesions
27 EXCEL: PCI Procedure Highlights Distal LM bifurcation: Provisional stenting recommended Hemodynamic support: Permitted, not usually required Staging: Liberal use permitted (<2 weeks preferred) Routine FU angiography: Not permitted
28 EXCEL: Status Given financial considerations, the sponsor has decided to cap enrollment at 1900 pts; the sponsor and PIs remain blinded With 2600 pts randomized, the trial had 90% power to demonstrated noninferiority between PCI and CABG for the primary endpoint of death/cva/mi at median FU 3 years With 1900 pts randomized, the trial has 80% power for the primary endpoint All 1900 pts have been randomized
29 NOBLE: Study Design 1200 pts with unprotected left main 26 EU sites With 3 additional non-complex lesions (excludes length >25 mm, CTO, 2-stent bifurcation, calcified or tortuous vessels) R PCI (Biomatrix BES) (N=600) CABG (N=600) Clinical follow-up: Through 5 years
30 NOBLE: Status All 1200 pts have been randomized c/o Evald Høj Christiansen
31 What Have I Learned from Treating Left Main Bifurcation Lesion in the Last 20 Years? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Heart Institute, Asan Medical Center, Seoul, Korea
32 Adjusted Hazard Ratios of MACCE Between CABG and PCI for LM Disease (N=2360) Outcomes of PCI Are Getting Better Over time! P for Interaction = 0.002and Better DES. Mainly due to more IVUS/FFR HR (95% CI) P value BMS ( ) 0.33 ( ) <0.001 Early DES ( ) 0.53 ( ) Late DES ( ) 1.01 ( ) PCI better 1 10 CABG better New Data from ASAN MAIN registry, 2014
33 Treatment for Distal LM Bifurcation Leson
34 Distal LM Stent Technique Less 2 stent approach P= Percent (%) Before Routine Use of FFR After Routine Use of FFR Two stent Single Stent cross over
35 Restenosis at 2 year Pooled Analysis in 403 Patients with LM PCI Using SES % Ostial and Shaft Bifurcation PCI Stent Crossover (provisional second stent) Is Clearly Better! 3/67 14/222 29/114 Single Two stent Kang et al. Circ Cardiovasc Interv 2011;4:
36 Distal LM Disease, Small LCX, Discrete Narrowing 75/M, Effort Chest Pain, Normal EF
37 Stent Crossover Predilation with Maverick 2.5mm Resolute Integrity 3.5mm
38 LCX Jailing, After Stent Crossover Positive FFR, Significant Jailing
39 Kissing Balloon Inflation! 3.5 mm Balloon Balloon Dilatation With Ryujin 2.0 mm 2.0 mm Balloon
40 After Kissing Balloon Inflation Negative FFR!
41 Angiographic Narrowing May Not Be Functional Narrowing! % 42% 7% (DS>50%) (FFR<0.80) Kang SJ, Catheterization and Cardiovascular Interventions. 2014;83(4):
42 If You Want To Treat LCX Ostium After Single Stent into LM/LAD Consider FFR First! Or DAC: Consider a Nordic Bifurcation approach and only stent if TIMI 2 flow. Ignore How Cx Looks
43 Salvage Branch with bail-out stenting Reverse Mini crush T-stent Cullotte Final Kissing Balloons important What is main branch?.most choose LM into LAD and salvage Cx. Some few do reverse
44 An approach for bifurcational lesions when using 2 stents as intention to treat Bifurcational lesion with no disease proximal to the bifurcation or very short left main V-Stent Pre Cross Section Bifurcational lesion with main branch disease extending proximal to the bifurcation and side branch which has origin with about 90 angle Short-Mini Crush/culotte T-Stent Post Pre Bifurcational lesion with main branch disease extending proximal to the bifurcation and side branch which ha origin with about 60 angle Post Pre Post
45 Chen, SL, et al. J Am Coll Cardiol Extra Step Compared to Mini-Crush Step 1: stenting side branch (mini crush) Step 2: balloon crush (step crush) Step 3: first kissing balloon inflation Step 4: stenting main vessel Step 5: final kissing balloon inflation
46 LM PCI: Key Points Heart Team approach Never ad hoc Be skilled at bifurcation stenting You may be comfortable doing LM PCI your new hospital may not Your partner s eyes and advice--critical Double scrub if possible EXCEL and NOBLE trials
Left Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationAbbott Vascular. PROTOCOL EXCEL Clinical Trial
Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationLeft Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationAssessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
More informationLEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore Disclosures Advisory Panel, Asian Medical Board Medtronics, Abbott Vascular. Speaker-honoraria,
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationLeft Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More informationCOMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationCount Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
More informationMost Patients with Elective Left Main Disease. Farrel Hellig
Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationR&M Solutions
PCI with DES versus CABG & syntax score Dr. Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology, Alexandria University, Egypt Head of Cardiology Department President of Egyptian Society of Cardiology
More informationLe# Main Interven-on: When Is It Appropriate. Femi Philip, MD Assistant Professor Of Medicine UC Davis
Le# Main Interven-on: When Is It Appropriate Femi Philip, MD Assistant Professor Of Medicine UC Davis Nil Disclosures Outline What is the LMCA? Should we revascularize severe LMCA disease? What revascularizacon
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationWhat do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationSYNTAX score before decision making! Corrado Tamburino, MD, PhD
SYNTAX score in left main - Tamburino TCT Asia Pacific Seoul, 27 April 2011 Slide 1 SYNTAX score before decision making! Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationIncidence and Treatment for LM In-Stent
Incidence and Treatment for LM In-Stent Restenosis Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology
More informationPCI in Left Main Disease: Are We There Yet?
PCI in Left Main Disease: Are We There Yet? Moderator Mark A. Turco, MD Director Center for Cardiac & Vascular Research Washington Adventist Hospital Takoma Park, Maryland Panelists David E. Kandzari,
More informationIntracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.
Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationCOMBAT- Revised Protocol
COMBAT- Revised Protocol Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationWhy I try to avoid side branch dilatation
Why I try to avoid side branch dilatation Hyeon-Cheol Gwon Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Why I don t kiss? I kiss! I prefer to discuss SB ballooning rather
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationNew Insight about FFR and IVUS MLA
New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική
ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική X. ΓΡΑΪΔΗΣ Επεμβατικός καρδιολόγος, FSCAI Kλινική Euromedica-Κυανούς Σταυρός, Θεσσαλονίκη The Fear factor The two words LEFT MAIN
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationPTCA 1979: : I
The SYNTAX Message is Clear: CABG is Preferred in Complex MVD Angioplasty Summit TCTAP 2012 Seoul, Korea April 2012 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationCoronary stenting: the appropriate use of FFR
Coronary stenting: the appropriate use of FFR Morton J. Kern, MD Professor of Medicine Chief of Cardiology LBVA Associate Chief Cardiology University California Irvine Orange, California To treat or not
More informationSouthern Thoracic Surgical Association CABG in 2012: Implications of the New ESC/EACTS Guidelines
Southern Thoracic Surgical Association 2011 CABG in 2012: Implications of the New ESC/EACTS Guidelines David P Taggart MD PhD FRCS Professor of Cardiovascular Surgery, University of Oxford Conflicts of
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationStent Fracture and Longitudinal Compression on CT Angiography between the
2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,
More informationPCIs on Intermediate Lesions NCDR Cath-PCI Registry
Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further
More informationThe Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study Five-Year Results in the French Subset René Koning, MD On behalf of the SYNTAX investigators Three-year
More informationAnatomical, physiological and clinical relevance of a side branch
Anatomical, physiological and clinical relevance of a side branch : Which branch really needs a stent? Bon-Kwon Koo, MD, PhD, Seoul, Korea Bifurcation lesion: The GREAT EQUALIZER! No intervention = Balloon
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of
More informationOCTOBER. OCT Optimised Bifurcation Event Reduction. A Nordic Baltic British clinical outcome trial
OCT Optimised Bifurcation Event Reduction A Nordic Baltic British clinical outcome trial NIELS RAMSING HOLM, Skejby Denmark Study start: OCTOBER 2016 OCTOBER LMCA or non-lmca bifurcations with SB 2.5mm
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationTrue Bifurcation LM Stenosis (Medina 1,1,1) With Very Extensive Calcification: CABG Or PCI?
True Bifurcation LM Stenosis (Medina,,) With Very Extensive Calcification: CABG Or PCI? T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia PCI or CABG for Unprotected
More informationPrognostic Value of Gated Myocardial Perfusion SPECT
Current Use of IVUS & FFR George D. Dangas, MD, PhD, FACC, FSCAI Professor of Medicine Mount Sinai School of Medicine Prognostic Value of Gated Myocardial Perfusion SPECT 0.6% / year, Cardiac Death and
More informationImplications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationDECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.
DECISION-CTO Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Seung-Jung Park, MD., PhD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationFRACTIONAL FLOW RESERVE: STANDARD OF CARE
FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW
More informationCPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
More informationGuidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI
Guidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationPCI for Stable Ischemic Heart Disease: What Happened in the Last Week?
PCI for Stable Ischemic Heart Disease: What Happened in the Last Week? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / NewYork Presbyterian Hospital
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationClinical case in perspective. Cases from Poland
Clinical case in perspective Cases from Poland Assoc. Prof. Jacek Legutko, MD, PhD President-Elect of the Association for Percutaneous Cardiovascular Interventions of the Polish Cardiac Society Institute
More informationΑγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center
Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center Δεν έχω οικονομική σχέση με φαρμακευτική εταιρία.
More informationReconciling the Results of the Randomized Trials
Management of Stable Angina in Multivessel Disease: Reconciling the Results of the Randomized Trials Eric A. Cohen MD, FRCPC Schulich Heart Centre Sunnybrook Health Sciences Centre Toronto ON ACC Rockies
More informationLésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille
Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an
More informationMedical Rx vs PCI vs CABG
Medical Rx vs PCI vs CABG S. Hinan Ahmed, MD Associate Professor: Cardiology and Cardiothoracic Surgery Program Director: Interventional Fellowship Program Assoc Editor: Cath and Cardiovasc Intervention
More information